Vascular cell molecule-1 as a prognostic marker in patients with end-stage heart failure

Acta Cardiologica Sinica

Volumn 20, Issue 2, 2004, Pages 94-104

  Chiang, Meng Cheng ^a   Yin, Wei Hsian ^a,b   Jen, Hsu Lung ^a   Wang, Jiann Jong ^a   Huang, Wen Pin ^a   Feng, An Ning ^a   Young, Mason Shing ^a  

^a CHENG HSIN GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cell adhesion molecules; Heart failure; Prognosis; Tumor necrosis factor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELL ADHESION MOLECULE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HEART VENTRICULOGRAPHY; HOSPITALIZATION; HUMAN; MALE; PATHOGENESIS; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 3943106052     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Oxenham H, Sharpe N. Prognostic stratification in heart failure: What's the point? Eur Heart J 2000;21:1815-6.
2. Stevenson LW, Couper G, Natterson B, et al. Target heart failure populations for newer therapies. Circulation 1995;92[Suppl II]:174-81.
3. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87(Suppl VI):6-16.
4. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999;100:999-1008.
5. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. International J Cardiol 2000;72:175-86.
6. Ruffolo RR Jr, Feuerstein GZ. Neurohormonal activation, oxygen free radicals, and apoptosis in the pathogenesis of congestive heart failure. J Cardiovasc Pharm 1998;32(Suppl I):S22-S30.
7. Givertz MM, Colucci WS. New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet 1998;352(Suppl I):34-8.
8. Finkel MS, Oddis CV, Jacob TD, et al. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
9. McGill SN, Ahmed NA, Christou NV. Endothelial cells: role in infection and inflammation. World J Surg 1998;22:171-8.
10. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995;76:803-8.
11. Menger MD, Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996;83-.588-601.
12. Andreassen AK, Nordoy I, Simonsen S, et al. Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol 1998;81:604-8.
13. Klein RM, Breuer R, Mundhenke M, et al. Circulating adhesion molecules (sICAM-1, sVCAM-1) in patients with suspected inflammatory heart muscle disease. Zeitschrift fur Kardiologie 1998;87:84-93.
14. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998;19:761-5.
15. Tousoulis D, Homaei H, Ahmed N, et al. Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy. Am Heart J 2001;141:277-80.
16. Yin WH, Chen JW, Jen HL, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail 2003;5:507-16.
17. Osborn L, Hession C, Tizard R, et al. Direct expression cloning of vascular cell adhesion molecule-1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell 1989;59:1203-11.
18. Pastore L, Tessiture A, Martinotti S, et al. Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo. Circulation 1999;100:1646-52.
19. Tummala PE, Chen XL, Sundell CL, et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100:1223-9.
20. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type I receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol 2000;35:714-21.
21. Drexler H, Kurz S, Jeserich M, et al. Effect of chronic angiotensin-converting enzyme inhibition on endothelial function in patients with chronic heart failure. Am J of Cardiol 1995;76:13E-18E.
22. Graciano AL, Bryant DD, White DJ, et al. Targeted disruption of ICAM-1, P-selectin genes improves cardiac function and survival in TNF-α transgenic mice. Am J Physiol Heart Circ Physiol 2001;280:H1464-H1471.